Ginkgo Bioworks Holdings, Inc. (DNA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 77 | 314 | 478 | 251 | 227 | 170 | 112 | 85 |
| Operating profit | $m | -315 | -291 | ||||||
| Net profit | $m | -127 | -1,830 | -2,105 | -893 | -547 | -313 | -291 | -245 |
| EPS reported | $ | -5.64 | -5.02 | ||||||
| Operating cashflow per share | $ | -3.08 | -2.74 | ||||||
| Capex per share | $ | 0.14 | 0.32 | ||||||
| FCF per share | $ | -3.22 | -3.06 | ||||||
| Free cash flow | $m | -179 | -190 | ||||||
| Net debt | $m | -423 | -302 | ||||||
| Book value equity | $m | 509 | 420 | ||||||
| Book value per share | $ | 9.17 | 6.77 | ||||||
| Number of shares | m | 55.46 | 62.09 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.91 | 1.10 | ||||||
| P/S LTM | x | 2.71 | 4.12 | ||||||
| P/FCF LTM | x | -2.58 | -2.42 | ||||||
| EV/EBITDA LTM | x | -2.88 | -3.51 | ||||||
| EV/Sales LTM | x | 4.31 | 6.92 | ||||||
| Earnings Yield LTM | % | -67.87% | -67.29% | ||||||
| FCF Yield | % | -38.78% | -41.25% | ||||||
| Quality | |||||||||
| ROE | % | -61.50% | -60.21% | ||||||
| ROIC | % | -30.05% | -31.63% | ||||||
| Operating margin | % | -1.85% | -2.60% | ||||||
| Gross margin | % | +81.48% | +80.09% | ||||||
| FCF/Sales | % | -105.04% | -169.96% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -25.06% | -50.73% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.41 | -0.47 | ||||||
| Net Debt/EBITDA | x | -1.07 | -1.53 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.83 | -0.72 | ||||||
| Gross debt/equity | x | 0.86 | 0.96 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ginkgo Bioworks Holdings, Inc. (DNA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free